Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
Date:10/1/2008

NEW YORK, Oct. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 21, 2008. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President-Finance and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until October 31, 2008 at both websites and also by dialing 1-866-859-6142 (US investors) or +1-706-679-7668 (international investors), ID 67369178

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that ma
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oil palm plantations are no substitute for tropical rainforests, a new study shows
2. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
3. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
4. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
7. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
8. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
9. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
10. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
11. Nanotube forests grown on silicon chips for future computers, electronics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 1Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 5Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 6Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 7Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 8Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 9Hormones May Affect Neurological Disease Risk 50513 1Hormones May Affect Neurological Disease Risk 50513 2Antibiotics May Boost Risk for Recurrent Ear Infection 50511 1Antibiotics May Boost Risk for Recurrent Ear Infection 50511 2
Mouse Anti-Mannose Receptor Monoclonal Antibody, Biotin Conjugated, Clone 15-Feb from Abcam
TE Buffer from Upstate
Mouse Anti-DcR1 Monoclonal Antibody, Biotin Conjugated, Clone DJR3 from Abcam
L-Selenomethionine from Calbiochem
Biology Products: